FDA sends letter to Novo Nordisk over potential GLP-1 side effects
FDA Scrutinizes Novo Nordisk: Reporting Lapses and Rising Safety Concerns with Ozempic & Wegovy The FDA recently issued a warning letter to Novo Nordisk, the manufacturer of Ozempic and Wegovy, citing failures to adequately report potential adverse effects and deaths linked to the popular GLP-1 medications. This action underscores growing scrutiny surrounding these drugs as … Read more